Barua, S., Murty, V. V., Iglesias, A., & Liao, J. (2025). A Novel EP300 Variant in an African American Girl With Global Developmental Delay and Leukemia. Molecular Genetics & Genomic Medicine, 13(6). Portico. https://doi.org/10.1002/mgg3.70102

Stubbins, R. J., Arnovitz, S., Vagher, J., Asom, A., Perpich, M., Pies, M., Akpan, I. J., Chew, E., Bridgers, J., Karsan, A., Rodgers, C., Koppayi, A., Basdag, H., Drazer, M. W., Das, S., Cheng, J., Osman, A. E. G., & Godley, L. A. (2025). Predisposition to hematopoietic malignancies by deleterious germline CHEK2 variants. Leukemia. https://doi.org/10.1038/s41375-025-02635-1

Bertulfo, K., Perez-Duran, P., Miller, H., Ma, C., Ambesi-Impiombato, A., Samon, J., Mackey, A., Lin, W.-H. W., Ferrando, A. A., & Palomero, T. (2025). Therapeutic targeting of the NOTCH1 and neddylation pathways in T cell acute lymphoblastic leukemia. Proceedings of the National Academy of Sciences, 122(14). https://doi.org/10.1073/pnas.2426742122

Shaw, R., Yoon, J. J., Johnston, H., Davidson, M. B., Siddon, A. J., Shallis, R. M., Chen, E. C., Burkart, M., Oh, T. S., Iyer, S. G., Madarang, E., Muthiah, C., Kassner, J., Rampal, R. K., Guru Murthy, G. S., Bradley, T. J., Abaza, Y., Garcia, J. S., Gupta, V., … Patel, A. A. (2025). Assessing AML-based risk criteria in patients with accelerated/blast-phase MPN treated with less-intensive therapy. Blood Advances. https://doi.org/10.1182/bloodadvances.2024015712

Hong, J., Sui, P., Li, Y., Xu, K. Y., Lee, J.-H., Wang, J., Chen, S., Zhang, P., Wingate, N., Noor, A., Yuan, Y., Hromas, R., Zhou, H., Hamamoto, K., Su, R., Yin, C. C., Ye, F., Quesada, A. E., Chen, J., … Xu, M. (2025). PSPC1 exerts an oncogenic role in AML by regulating a leukemic transcription program in cooperation with PU.1. Cell Stem Cell. https://doi.org/10.1016/j.stem.2025.01.010

Anderson, G. A., Hernandez, M., Quinde, C. A., Thompson, Z., Binder-Blaser, V., Taylor, A. M., & Kathrein, K. L. (2025). Loss of ING4 enhances hematopoietic regeneration in multipotent progenitor cells. PLOS ONE, 20(2), e0316256. https://doi.org/10.1371/journal.pone.0316256

Maurer, K., Park, C. Y., Mani, S., Borji, M., Raths, F., Gouin, K. H., Penter, L., Jin, Y., Zhang, J. Y., Shin, C., Brenner, J. R., Southard, J., Krishna, S., Lu, W., Lyu, H., Abbondanza, D., Mangum, C., Olsen, L. R., Lawson, M. J., … Azizi, E. (2025). Coordinated immune networks in leukemia bone marrow microenvironments distinguish response to cellular therapy. Science Immunology, 10(103). https://doi.org/10.1126/sciimmunol.adr0782

Gui, G., Ravindra, N., Hegde, P. S., Andrew, G., Mukherjee, D., Wong, Z., Auletta, J. J., El Chaer, F., Chen, E. C., Chen, Y.-B., Corner, A., Devine, S. M., Iyer, S. G., Jimenez Jimenez, A. M., De Lima, M. J. G., Litzow, M. R., Kebriaei, P., Saber, W., Spellman, S. R., … Hourigan, C. S. (2024). Measurable residual mutated IDH1 before allogeneic transplant for acute myeloid leukemia. Bone Marrow Transplantation. https://doi.org/10.1038/s41409-024-02447-4

Gui, G., Ravindra, N., Hegde, P. S., Andrew, G., Mukherjee, D., Wong, Z., Auletta, J. J., El Chaer, F., Chen, E. C., Chen, Y.-B., Corner, A., Devine, S. M., Iyer, S. G., Jimenez Jimenez, A. M., De Lima, M. J. G., Litzow, M. R., Kebriaei, P., Saber, W., Spellman, S. R., … Hourigan, C. S. (2024). Measurable residual mutated IDH2 before allogeneic transplant for acute myeloid leukemia. Bone Marrow Transplantation. https://doi.org/10.1038/s41409-024-02449-2

Thompson, Z., Anderson, G. A., Hernandez, M., Alfaro Quinde, C., Marchione, A., Rodriguez, M., Gabriel, S., Binder, V., Taylor, A. M., & Kathrein, K. L. (2024). Ing4-deficiency promotes a quiescent yet transcriptionally poised state in hematopoietic stem cells. IScience, 27(8), 110521. https://doi.org/10.1016/j.isci.2024.110521

Hassan, N., Yi, H., Malik, B., Gaspard-Boulinc, L., Samaraweera, S. E., Casolari, D. A., Seneviratne, J., Balachandran, A., Chew, T., Duly, A., Carter, D. R., Cheung, B. B., Norris, M., Haber, M., Kavallaris, M., Marshall, G. M., Zhang, X. D., Liu, T., Wang, J., … Wang, J. Y. (2024). Loss of the stress sensor GADD45A promotes stem cell activity and ferroptosis resistance in LGR4/HOXA9-dependent AML. Blood, 144(1), 84–98. https://doi.org/10.1182/blood.2024024072

Patel, A. A., Yoon, J. J., Johnston, H., Davidson, M. B., Shallis, R. M., Chen, E. C., Burkart, M., Oh, T. S., Iyer, S. G., Madarang, E., Muthiah, C., Gross, I., Dean, R., Kassner, J., Viswabandya, A., Madero-Marroquin, R., Rampal, R. K., Guru Murthy, G. S., Bradley, T., … Odenike, O. (2024). Treatment approach and outcomes of patients with accelerated/blast-phase myeloproliferative neoplasms in the current era. Blood Advances, 8(13), 3468–3477. https://doi.org/10.1182/bloodadvances.2024012880

Infante, P., Conenna, M., Adabbo, G., Bufalieri, F., Bottero, M., Severini, L. L., Bartolini, F., & Marcotullio, L. D. (2024). MDB-28. THE CYTOSKELETON REGULATORS FORMINS CONTROL THE SHH PATHWAY AND ARE INVOLVED IN MEDULLOBLASTOMA TUMORIGENESIS. Neuro-Oncology, 26(Supplement_4), 0–0. https://doi.org/10.1093/neuonc/noae064.477

Lu, Z., Wang, Y., Assumpção, A. L. F. V., Liu, P., Kopp, A., Saka, S., Mcilwain, S. J., Viny, A. D., Brand, M., & Pan, X. (2024). Yin Yang 1 regulates cohesin complex protein SMC3 in mouse hematopoietic stem cells. Blood Advances, 8(12), 3076–3091. https://doi.org/10.1182/bloodadvances.2023011411

Madarang, E., Lykon, J., Zhao, W., Sekeres, M. A., Bradley, T., Chandhok, N. S., Taylor, J., Venugopal, S., Koru-Sengul, T., Iyer, S. G., Gilbert, J. S., Miller, R. M., Nanni, J., Zacheo, I., Mattei, A., Al Ali, N., Kishtagari, A., Marconi, G., Sallman, D. A., … Watts, J. (2024). Venetoclax and hypomethylating agents in octogenarians and nonagenarians with acute myeloid leukemia. Blood Neoplasia, 1(2), 100016. https://doi.org/10.1016/j.bneo.2024.100016

Vilarello, B. J., Jacobson, P. T., Gudis, D. A., & Overdevest, J. B. (2024). B-cell Lymphoblastic Lymphoma Presenting as a Sinonasal Mass: A Case Report. Cureus. https://doi.org/10.7759/cureus.58132

Verma, A., Chi, Y.-Y., Malvar, J., Lamble, A., Chaudhury, S., Agarwal, A., Li, H.-T., Liang, G., Leong, R., Brown, P. A., Kaplan, J., Schafer, E. S., Slone, T., Pauly, M., Chang, B. H., Stieglitz, E., Wayne, A. S., Hijiya, N., & Bhojwani, D. (2024). Nivolumab Plus 5-Azacitidine in Pediatric Relapsed/Refractory Acute Myeloid Leukemia (AML): Phase I/II Trial Results from the Therapeutic Advances in Childhood Leukemia and Lymphoma (TACL) Consortium. Cancers, 16(3), 496. https://doi.org/10.3390/cancers16030496

Paudel, B. B., Tan, S.-F., Fox, T. E., Ung, J., Golla, U., Shaw, J. J. P., Dunton, W., Lee, I., Fares, W. A., Patel, S., Sharma, A., Viny, A. D., Barth, B. M., Tallman, M. S., Cabot, M., Garrett-Bakelman, F. E., Levine, R. L., Kester, M., Feith, D. J., … Loughran, T. P. (2024). Acute myeloid leukemia stratifies as 2 clinically relevant sphingolipidomic subtypes. Blood Advances, 8(5), 1137–1142. https://doi.org/10.1182/bloodadvances.2023010535

Daver, N., Zeidner, J. F., Yuda, J., Watts, J. M., Levis, M. J., Fukushima, K., Ikezoe, T., Ogawa, Y., Brandwein, J., Wang, E. S., Miyazaki, Y., Pardee, T., Hosono, N., Shima, T., Yokoyama, H., Asada, N., Jurcic, J., Cai, H., Watanabe, A., … Erba, H. P. (2023). Phase 1/2 First-in-Human Study of the Menin-MLL Inhibitor DSP-5336 in Patients with Relapsed or Refractory Acute Leukemia. Blood, 142(Supplement 1), 2911–2911. https://doi.org/10.1182/blood-2023-179252

Gui, G., Dillon, L. W., Ravindra, N., Hegde, P. S., Andrew, G., Mukherjee, D., Wong, Z., Auletta, J. J., El Chaer, F., Chen, E. C., Chen, Y.-B., Corner, A., Devine, S. M., Iyer, S. G., Jimenez Jimenez, A. M., de Lima, M., Litzow, M. R., Kebriaei, P., Saber, W., … Hourigan, C. S. (2023). Measurable Residual IDH2 before Allogeneic Transplant for Acute Myeloid Leukemia. Blood, 142(Supplement 1), 424–424. https://doi.org/10.1182/blood-2023-186822

Wang, E. S., Jonas, B. A., Watts, J. M., Jurcic, J., Ferrell, P. B., Dinner, S. N., Yang, J., Seiter, K., Mims, A., Donnellan, W. B., Blum, W., & Cortes, J. (2023). Factors Impacting Response to Olutasidenib in Patients with mIDH1 Acute Myeloid Leukemia. Blood, 142(Supplement 1), 6047–6047. https://doi.org/10.1182/blood-2023-187584

Cortes, J., Jurcic, J., Baer, M. R., Blum, W., Ferrell, P. B., Jonas, B. A., Lee, S., Mims, A., Patel, S. A., Schiller, G. J., Yang, J., & Watts, J. M. (2023). Olutasidenib for the Treatment of mIDH1 Acute Myeloid Leukemia in Patients Relapsed or Refractory to Hematopoietic Stem Cell Transplant, Prior mIDH1 Inhibitor, or Venetoclax. Blood, 142(Supplement 1), 2888–2888. https://doi.org/10.1182/blood-2023-187861

DiPersio, J., Cooper, B. W., Suh, H. C., Koura, D., Bernard, L., Shah, N. N., Walter, R. B., Perales, M.-A., Mapara, M., Tamari, R., Loken, M. R., Breitschwerdt, K., Nath, S., Raffel, G. D., & Koehne, G. (2023). Trem-Cel, a CRISPR/Cas9 Gene-Edited Allograft Lacking CD33, Shows Rapid Primary Engraftment with CD33-Negative Hematopoiesis in Patients with High-Risk Acute Myeloid Leukemia (AML) and Avoids Hematopoietic Toxicity during Gemtuzumab Ozogamicin (GO) Maintenance Post-Hematopoietic Cell Transplant (HCT). Blood, 142(Supplement 1), 483–483. https://doi.org/10.1182/blood-2023-190037

Xu, J. J., Chen, Y., Pantazi, J., Fernando, S., Alija, B., Sudunagunta, V., Bhagat, G., Bowman, R. L., & Viny, A. D. (2023). Stag2-Cohesin Loss Attenuates Flt3 ITD Myeloid Blast Expansion Yet Preserves Mutant HSC. Blood, 142(Supplement 1), 2756–2756. https://doi.org/10.1182/blood-2023-190702

Gui, G., Dillon, L. W., Ravindra, N., Hegde, P. S., Andrew, G., Mukherjee, D., Wong, Z., Auletta, J. J., El Chaer, F., Chen, E. C., Chen, Y.-B., Corner, A., Devine, S. M., Iyer, S. G., Jimenez Jimenez, A. M., de Lima, M., Litzow, M. R., Kebriaei, P., Saber, W., … Hourigan, C. S. (2023). Measurable Residual IDH1 before Allogeneic Transplant for Acute Myeloid Leukemia. Blood, 142(Supplement 1), 4316–4316. https://doi.org/10.1182/blood-2023-186376

Patel, A. A., Yoon, J. J., Johnston, H., Davidson, M. B., Viswabandya, A., Shallis, R. M., Chen, E. C., Burkart, M., Oh, T. S., Iyer, S. G., Madarang, E., Muthiah, C., Dean, R., Kassner, J., Rampal, R. K., Guru Murthy, G. S., Bradley, T., Abaza, Y., Garcia, J. S., … Odenike, O. (2023). Outcomes of Patients with Accelerated/Blast-Phase MPNs That Received Allogeneic Stem-Cell Transplant in the Current Era of Myeloid Therapies. Blood, 142(Supplement 1), 3192–3192. https://doi.org/10.1182/blood-2023-174790

Garcia-Manero, G., Odenike, O., Fleming, S., Roboz, G. J., Jacoby, M., Cunningham, I., Kreuzer, K.-A., Enjeti, A. K., Baer, M. R., Cook, R., Jurcic, J., Ku, G., Zhou, Y., Hoffman, D., Potluri, J., & Garcia, J. S. (2023). Combination of Venetoclax and Azacitidine in Patients with Treatment-Naive, High-Risk Myelodysplastic Syndromes with Responses Leading to Stem Cell Transplantation. Blood, 142(Supplement 1), 1868–1868. https://doi.org/10.1182/blood-2023-187102

Tolu, S. S., Piorczynski, T. B., Pazos, M., Estrella, B., Huang, W., Ryu, Y. K., Cherng, H.-J. J., Pro, B., & Amengual, J. E. (2023). JAK1/2 Inhibition Modulates Key Markers of Lymphomagenesis in 9p24.1 Amplified Lymphoma, Priming for Enhanced Antigenicity. Blood, 142(Supplement 1), 6118–6118. https://doi.org/10.1182/blood-2023-180875

Chernak, B., Galan-Diez, M., Ali, A. M., Cuesta-Dominguez, A., Chen, Z., Koehnke, T., Majeti, R., Carroll, M., Raza, A., & Kousteni, S. (2023). Serum Amyloid A1 (SAA1) Secreted By the Stromal Microenvironment Drives Malignant Clonal Proliferation in Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML). Blood, 142(Supplement 1), 4118–4118. https://doi.org/10.1182/blood-2023-174485

Shi, A., Ali, A. M., Cann, G., Shaknovich, R., Venn, O., Raza, A., & Liu, Q. (2023). Methylation Biology of a Blood-Based MDS Risk Stratification Test. Blood, 142(Supplement 1), 4599–4599. https://doi.org/10.1182/blood-2023-180256

Bernard, E., Hasserjian, R., Greenberg, P. L., Arango Ossa, J. E., Creignou, M., Nannya, Y., Tuechler, H., Medina-Martínez, J. S., Levine, M. F., Jädersten, M., Germing, U., Sanz, G., van de Loosdrecht, A. A., Kosmider, O., Follo, M. Y., Thol, F., Zamora, L., Pinheiro, R. F., Pellagatti, A., … Papaemmanuil, E. (2023). Molecular Taxonomy of Myelodysplastic Syndromes and Its Clinical Implications. Blood, 142(Supplement 1), 997–997. https://doi.org/10.1182/blood-2023-186863

Cochran, J. D., Yura, Y., Thel, M. C., Doviak, H., Polizio, A. H., Arai, Y., Arai, Y., Horitani, K., Park, E., Chavkin, N. W., Kour, A., Sano, S., Mahajan, N., Evans, M., Huba, M., Naya, N. M., Sun, H., Ban, Y. H., Hirschi, K. K., … Walsh, K. (2023). Clonal Hematopoiesis in Clinical and Experimental Heart Failure With Preserved Ejection Fraction. Circulation, 148(15), 1165–1178. https://doi.org/10.1161/circulationaha.123.064170

Mack, E., Dougher, M., Murter, M., Tanhehco, Y., Siegel, D., Fesnak, A., Bhoj, V., Kambayashi, T., Aqui, N., & O’Doherty, U. (2023). OA5‐AM23‐MN‐36 | Red Cell Exchange for Rapid Leukoreduction in Adults with Hyperleukocytosis and Leukostasis. Transfusion, 63(S5). Portico. https://doi.org/10.1111/trf.16_17554

Yu, Z., Fidler, T. P., Ruan, Y., Vlasschaert, C., Nakao, T., Uddin, M. M., Mack, T., Niroula, A., Heimlich, J. B., Zekavat, S. M., Gibson, C. J., Griffin, G. K., Wang, Y., Peloso, G. M., Heard-Costa, N., Levy, D., Vasan, R. S., Aguet, F., Ardlie, K. G., … Natarajan, P. (2023). Genetic modification of inflammation- and clonal hematopoiesis–associated cardiovascular risk. Journal of Clinical Investigation, 133(18). https://doi.org/10.1172/jci168597

Pratz, K. W., Cherry, M., Altman, J. K., Cooper, B. W., Podoltsev, N. A., Cruz, J. C., Lin, T. L., Schiller, G. J., Jurcic, J. G., Asch, A., Wu, R., Hill, J. E., Gill, S. C., James, A. J., Rich, E. S., Hasabou, N., Perl, A. E., & Levis, M. J. (2023). Gilteritinib in Combination With Induction and Consolidation Chemotherapy and as Maintenance Therapy: A Phase IB Study in Patients With Newly Diagnosed AML. Journal of Clinical Oncology, 41(26), 4236–4246. https://doi.org/10.1200/jco.22.02721

Niehus, H., Sabile, J., Maziarz, R. T., Meyers, G., Cook, R., Gandhi, A., Saultz, J. N., Rakshe, S., Kaempf, A., Braun, T., & Migdady, Y. (2023). POSTER: MDS-009 Enhanced Survival of Chronic Myelomonocytic Leukemia (CMML)-Dysplastic Over the Proliferative Subtype After Allogeneic Hematopoietic Cell Transplantation: A Tertiary Center Experience. Clinical Lymphoma Myeloma and Leukemia, 23, S180. https://doi.org/10.1016/s2152-2650(23)00576-1

Coughlan, A., Klijn, S. L., Xiao, H., White, B., Litkiewicz, M., Kadambi, A., Sichevaya, A., Hnoosh, A., Miteva, D., & Yucel, A. (2023). POSTER: MDS-008 Impact of Timing of Achievement of Red Blood Cell-Transfusion Independence (RBC-TI) on Clinical Outcomes and Resource Utilization in Lower-Risk Myelodysplastic Syndromes (LR-MDS). Clinical Lymphoma Myeloma and Leukemia, 23, S180. https://doi.org/10.1016/s2152-2650(23)00575-x

Schlenk, R. F., Montesinos, P., Romero-Aguilar, A., Vrhovac, R., Patkowska, E., Kim, H.-J., Zak, P., Wang, P.-N., Hanyok, J., Liu, L., Kamel, Y. M., Lesegretain, A., Cortes, J., Sekeres, M. A., Dombret, H., Amadori, S., Wang, J., Perl, A. E., Levis, M. J., & Erba, H. P. (2023). POSTER: CT-186 Impact of Allogeneic Hematopoietic Cell Transplantation (allo-HCT) in First Complete Remission (CR1) in Addition to FLT3 Inhibition With Quizartinib in Acute Myeloid Leukemia (AML) With FLT3–Internal Tandem Duplication (FLT3-ITD): Results from the QuANTUM-First Trial. Clinical Lymphoma Myeloma and Leukemia, 23, S229. https://doi.org/10.1016/s2152-2650(23)00885-6

Lee, T. D., Aisner, D. L., David, M. P., Eno, C. C., Gagan, J., Gocke, C. D., Guseva, N. V., Haley, L., Jajosky, A. N., Jones, D., Mansukhani, M. M., Mroz, P., Murray, S. S., Newsom, K. J., Paulson, V., Roy, S., Rushton, C., Segal, J. P., Senaratne, T. N., … Kim, A. S. (2023). Current clinical practices and challenges in molecular testing: a GOAL Consortium Hematopathology Working Group report. Blood Advances, 7(16), 4599–4607. https://doi.org/10.1182/bloodadvances.2023010149

Levy, B., Baughn, L. B., Akkari, Y., Chartrand, S., LaBarge, B., Claxton, D., Lennon, P. A., Cujar, C., Kolhe, R., Kroeger, K., Pitel, B., Sahajpal, N., Sathanoori, M., Vlad, G., Zhang, L., Fang, M., Kanagal-Shamanna, R., & Broach, J. R. (2023). Optical genome mapping in acute myeloid leukemia: a multicenter evaluation. Blood Advances, 7(7), 1297–1307. https://doi.org/10.1182/bloodadvances.2022007583

Feng, J., Hsu, P.-F., Esteva, E., Labella, R., Wang, Y., Khodadadi-Jamayran, A., Pucella, J., Liu, C. Z., Arbini, A. A., Tsirigos, A., Kousteni, S., & Reizis, B. (2023). Haplodeficiency of the 9p21 tumor suppressor locus causes myeloid disorders driven by the bone marrow microenvironment. Blood, 142(5), 460–476. https://doi.org/10.1182/blood.2022018512

Alsina, M., Dhodapkar, M., Berdeja, J., Patel, K., Richard, S., Vij, R., Leleu, X., Egan, D., Leif Bergsagel, P., Ran, R., Usmani, S. Z., Truppel-Hartmann, A., Basudhar, D., Thompson, E., Zheng, X., Zhong, X., Greggio, C., Popa Mckiver, M., Carrasco Alfonso, M., & Siegel, D. (2023). P871: IDECABTAGENE VICLEUCEL (IDE-CEL) IN PATIENTS WITH AN INADEQUATE RESPONSE TO FRONTLINE AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT): RESULTS FROM KARMMA-2 COHORT 2C. HemaSphere, 7(S3), e90596a3. https://doi.org/10.1097/01.hs9.0000970388.90596.a3

Ali, A. M., BenMohamed, F., Decina, A., Mukherjee, S., Levi, S., Garrido Castillo, L. N., Bréchot, D., Jurcic, J., Raza, A., & Paterlini Bréchot, P. (2023). Circulating cancer giant cells with unique characteristics frequently found in patients with myelodysplastic syndromes (MDS). Medical Oncology, 40(7). https://doi.org/10.1007/s12032-023-02064-z

Murthy, G. S. G., Kim, S., Estrada-Merly, N., Abid, M. B., Aljurf, M., Assal, A., Badar, T., Badawy, S. M., Ballen, K., Beitinjaneh, A., Cerny, J., Chhabra, S., DeFilipp, Z., Dholaria, B., Perez, M. A. D., Farhan, S., Freytes, C. O., Gale, R. P., Ganguly, S., … Saber, W. (2023). Association between the choice of the conditioning regimen and outcomes of allogeneic hematopoietic cell transplantation for myelofibrosis. Haematologica, 108(7), 1900–1908. https://doi.org/10.3324/haematol.2022.281958

Sarkaria, S. M., Zhou, J., Bao, S., Zhao, W., Fang, Y., Que, J., Bhagat, G., Zhang, C., & Ding, L. (2023). Systematic dissection of coordinated stromal remodeling identifies Sox10 glial cells as a therapeutic target in myelofibrosis. Cell Stem Cell, 30(6), 832-850.e6. https://doi.org/10.1016/j.stem.2023.05.002

Sallman, D. A., Al Malki, M. M., Asch, A. S., Wang, E. S., Jurcic, J. G., Bradley, T. J., Flinn, I. W., Pollyea, D. A., Kambhampati, S., Tanaka, T. N., Zeidner, J. F., Garcia-Manero, G., Jeyakumar, D., Komrokji, R., Lancet, J., Kantarjian, H. M., Gu, L., Zhang, Y., Tan, A., … Daver, N. G. (2023). Magrolimab in Combination With Azacitidine in Patients With Higher-Risk Myelodysplastic Syndromes: Final Results of a Phase Ib Study. Journal of Clinical Oncology, 41(15), 2815–2826. https://doi.org/10.1200/jco.22.01794

de Botton, S., Cluzeau, T., Vigil, C., Cook, R. J., Rousselot, P., Rizzieri, D. A., Liesveld, J. L., Fenaux, P., Braun, T., Banos, A., Jurcic, J. G., Sekeres, M. A., Savona, M. R., Roboz, G. J., Bixby, D., Madigan, K., Volkert, A., Stephens, K., Kang-Fortner, Q., … Stein, E. M. (2023). Targeting RARA overexpression with tamibarotene, a potent and selective RARα agonist, is a novel approach in AML. Blood Advances, 7(9), 1858–1870. https://doi.org/10.1182/bloodadvances.2022008806

Putta, S., Young, B. A., Levine, J. E., Reshef, R., Nakamura, R., Strouse, C., Perales, M.-A., Howard, A., Pine, P., Shi, J., Zhang, P., Ho, V. T., & Saber, W. (2023). Prognostic Biomarkers for Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome in Myeloablative Allogeneic Hematopoietic Cell Transplantation: Results from the Blood and Marrow Transplant Clinical Trials Network 1202 Study. Transplantation and Cellular Therapy, 29(3), 166.e1-166.e10. https://doi.org/10.1016/j.jtct.2022.11.024

Vela, P. S., Wang, R., Tran, D., Benitez, A. M., Krishnan, A., O’Connor, K., Liu, W., Kleppe, M., Bowman, R., Cai, S., Shih, A., Wang, N., Esteller, M., Bolton, K., Tall, A., & Levine, R. (2023). 3168 – TARGETING JAK1 SIGNALING FOR MOLECULAR PREVENTION IN CLONAL HEMATOPOIESIS. Experimental Hematology, 124, S133. https://doi.org/10.1016/j.exphem.2023.06.275

Stenger, E., Xiang, Y., Wetzel, M., Gillespie, S., Chellapandian, D., Shah, R., Arnold, S. D., Bhatia, M., Chaudhury, S., Eckrich, M. J., Kanter, J., Kasow, K. A., Krajewski, J., Nickel, R. S., Ngwube, A. I., Olson, T. S., Rangarajan, H. G., Wobma, H., Guilcher, G. M. T., … Abraham, A. (2023). Long-Term Organ Function After HCT for SCD: A Report From the Sickle Cell Transplant Advocacy and Research Alliance. Transplantation and Cellular Therapy, 29(1), 47.e1-47.e10. https://doi.org/10.1016/j.jtct.2022.10.012